News
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
10d
GlobalData on MSNEli Lilly and GSK drive South Korea’s drug licensing activity
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly CEO David Ricks ...
4d
TipRanks on MSNEli Lilly (LLY) Signs $1.3 Billion Deal with Superluminal to Discover Future Drugs Using AI
Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see ...
Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe may ...
Hosted on MSN24d
Lilly set for strong quarter after Novo profit warning - MSN
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo© Thomson Reuters ...
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world ...
Lilly said its share of the U.S. market for incretins, the class of drugs to which diabetes drug Mounjaro and weight-loss drug Zepbound belong, increased to 57% during the quarter.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results